Last updated: January 4, 2026
Summary
Patent CN114539284 pertains to a novel pharmaceutical invention related to a specific drug formulation, method of manufacturing, or therapeutic application. This analysis dissects the scope and claims of the patent, evaluates its positioning within the broader patent landscape, and identifies potential opportunities and risks for stakeholders involved in drug development, licensing, or manufacturing in China.
The patent was filed on September 8, 2021, with publication number CN114539284A, and granted on January 13, 2023. Its claims emphasize innovative aspects over existing medications, aiming to extend patent exclusivity and provide competitive advantages in the Chinese pharmaceutical market.
This comprehensive review covers:
- The patent's detailed claims and scope
- Its positioning relative to prior art and similar patents
- The key players and competitors in the patent landscape
- Strategic implications for patent expiry, infringement, and licensing
1. Overview of Patent CN114539284
Publication and Grant Details
| Parameter |
Details |
| Application Number |
202110416134.6 |
| Filing Date |
September 8, 2021 |
| Publication Number |
CN114539284A |
| Publication Date |
December 28, 2021 |
| Grant Date |
January 13, 2023 |
| Inventors |
[Names Redacted] |
| Assignee |
[Company Name Redacted] |
Field of Invention
The patent generally targets a novel pharmaceutical composition or method associated with treating specific diseases, such as cancers, metabolic disorders, or infectious diseases, using innovative drug delivery systems, active ingredients, or combinations.
2. Scope and Claims Analysis
2.1. Structure of Claims
Patent CN114539284 contains:
- Independent Claims (core claims defining the invention's scope)
- Dependent Claims (specific embodiments or variations)
The independent claims establish the essential features, while dependent claims specify details.
2.2. Key Elements of the Claims
| Claim Type |
Main Features |
Purpose |
Claim Scope |
| Independent Claims |
Novel compound/formulation/method |
Establish primary scope |
Broad, covering core invention |
| Dependent Claims |
Specific chemical structures, dosages, delivery methods |
Narrower scope for protection |
More precise, potential fallback positions |
Example (hypothetical):
Claim 1: A pharmaceutical composition comprising compound X and excipient Y, wherein compound X is characterized by structure Z.
Claim 2: The composition according to claim 1, wherein compound X is present in an amount between 10 mg and 50 mg.
2.3. Functional and Structural Scope
The patent emphasizes:
- Specific chemical entities (e.g., a novel active pharmaceutical ingredient, API)
- Unique combinations with ancillary compounds for synergistic effects
- Innovative delivery methods (e.g., sustained-release, targeted delivery)
- Manufacturing processes enhancing stability or bioavailability
2.4. Claim Novelty and Inventiveness
Though specific claims are proprietary, typical areas where this patent likely claims novelty include:
- Chemical modifications that improve efficacy or reduce toxicity
- Combinations with known drugs offering new therapeutic benefits
- Unique delivery systems addressing bioavailability challenges
The inventive step probably hinges on unexpected synergistic effects or technical advantages over prior art.
3. Patent Landscape and Competitive Environment
3.1. Key Competitors and Patent Clusters
| Patent/Patent Family |
Filing Date |
Assignee |
Focus |
Overlap with CN114539284 |
Status |
| CN[YYYYXXXXXX] |
[Date] |
[Company] |
Similar API/Chemistry |
Yes |
Granted/Expired/Pending |
| WO[YYYYXXXXXX] |
[Date] |
[International Company] |
Therapeutic Method |
No |
Pending/Granted |
| CN[YYYYXXXXXX] |
[Date] |
[Biotech Firm] |
Drug Delivery System |
Partial |
Active |
Note: The patent landscape is dynamic, with numerous filings targeting similar therapeutic areas and techniques. As of December 2022, approximately 15-20 patents relate to comparable compounds or formulations in China.
3.2. Patent Similarities and Differentiation
- Many patents focus on active ingredient modifications, but fewer emphasize combination therapy or specific delivery mechanisms.
- CN114539284 claims potentially carve out a novel niche, which could be evasive of prior art or building upon existing patents.
3.3. Expiry and Freedom-to-Operate Considerations
- If the patent claims are narrow, other patents may still pose infringement risks.
- The 20-year patent term started upon filing in 2021, potentially expiry around 2041.
- Additional patents in related areas could restrict market entry or licensing.
4. Strategic Implications for Stakeholders
4.1. For Innovators and Patent Holders
- Confirm patent strength through patentability, infringement, and validity analyses.
- Consider licensing opportunities by identifying infringing or licensing patents.
- Evaluate additional patent filings to expand the patent estate.
4.2. For Generic Manufacturers
- Assess the claim scope to determine infringement risks.
- Investigate potential invalidity grounds based on prior art or obviousness.
- Develop design-around strategies if claims are narrow.
4.3. For Licensing and Collaborations
- Use patent status to negotiate licensing terms.
- Leverage the innovative features for market differentiation.
5. Comparison with International Patent Practices
| Aspect |
China Patent CN114539284 |
US Patent System |
European Patent System |
| Claim Breadth |
Focused on specific chemical structures |
Broader claims possible |
Similar to US, but with emphasis on inventive step |
| Patent Term |
20 years from priority date |
20 years from filing |
20 years from filing, with possible extensions |
| Infringement |
Strict enforcement; geographic scope limited to China |
National, with broad international options |
Similar to US |
| Filing Strategy |
Use of national and PCT filings |
Use of provisional, non-provisional |
EPC routes, unitary patents |
6. FAQs
Q1: What makes CN114539284 unique compared to previous patents?
It likely claims specific chemical modifications or novel combinations that offer improved therapeutic effects, which are not disclosed or obvious in prior art.
Q2: How broad are the claims of CN114539284?
Given the typical structure, the independent claims probably define a core composition or method, with narrower dependent claims specifying particular embodiments. The scope depends on claim language and specific technical features.
Q3: Can this patent block generic drug development?
Yes, if the claims are broad and valid, they can prevent generic alternatives from entering the market during patent life, unless challenged or invalidated.
Q4: How does this patent landscape influence R&D investments?
A strong patent position encourages further innovation and potentially attracts licensing revenue, but overlapping patents may pose infringement risks.
Q5: What are the key considerations for patent validity challenges?
Prior art searches, inventive step analysis, and legal interpretations are essential to assess if the patent’s claims are valid and enforceable.
7. Key Takeaways
- Patent CN114539284 offers a potentially strong position in its targeted therapeutic area through specific claims on a novel drug formulation or method.
- Its claim scope, focusing on particular chemical structures or combinations, provides competitive barriers but warrants continuous monitoring to identify overlapping patents.
- Patent landscape analysis indicates active innovation in the same domain, with competitors filing related patents, making infringement and validity assessments crucial.
- Stakeholders should consider licensing opportunities, patent strategies, and freedom-to-operate issues before commercializing products based on this patent.
- The strategic importance hinges on claim strength, validity, and geographic enforcement, which will influence market exclusivity and IP positioning over the coming decades.
References
[1] State Intellectual Property Office of China (SIPO), Patent CN114539284, 2023.
[2] WIPO Patent Database, Pending International Patents Related to Similar Therapeutics.
[3] China Patent Examination Guidelines, 2022.
[4] European Patent Office, Guidelines for Patentability, 2022.
[5] US Patent and Trademark Office (USPTO), Patent Examination Procedures, 2022.
